140 related articles for article (PubMed ID: 8396562)
1. Synthetic linear and cyclic glucagon antagonists.
Dharanipragada R; Trivedi D; Bannister A; Siegel M; Tourwe D; Mollova N; Schram K; Hruby VJ
Int J Pept Protein Res; 1993 Jul; 42(1):68-77. PubMed ID: 8396562
[TBL] [Abstract][Full Text] [Related]
2. Synthetic glucagon antagonists and partial agonists.
Zechel C; Trivedi D; Hruby VJ
Int J Pept Protein Res; 1991 Aug; 38(2):131-8. PubMed ID: 1664420
[TBL] [Abstract][Full Text] [Related]
3. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
[TBL] [Abstract][Full Text] [Related]
4. Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists.
Van Tine BA; Azizeh BY; Trivedi D; Phelps JR; Houslay MD; Johnson DG; Hruby VJ
Endocrinology; 1996 Aug; 137(8):3316-22. PubMed ID: 8754757
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of two glucagon antagonists: receptor binding, adenylate cyclase, and effects on blood plasma glucose levels.
Gysin B; Johnson DG; Trivedi D; Hruby VJ
J Med Chem; 1987 Aug; 30(8):1409-15. PubMed ID: 3039134
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity studies of hydrophobic amino acid replacements at positions 9, 11 and 16 of glucagon.
Sturm NS; Hutzler AM; David CS; Azizeh BY; Trivedi D; Hruby VJ
J Pept Res; 1997 Apr; 49(4):293-9. PubMed ID: 9176812
[TBL] [Abstract][Full Text] [Related]
7. The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple replacement analogues of glucagon.
Azizeh BY; Ahn JM; Caspari R; Shenderovich MD; Trivedi D; Hruby VJ
J Med Chem; 1997 Aug; 40(16):2555-62. PubMed ID: 9258362
[TBL] [Abstract][Full Text] [Related]
8. New glucagon analogues with conformational restrictions and altered amphiphilicity: effects on binding, adenylate cyclase and glycogenolytic activities.
Hruby VJ; Gysin B; Trivedi D; Johnson DG
Life Sci; 1993; 52(10):845-55. PubMed ID: 8445980
[TBL] [Abstract][Full Text] [Related]
9. Receptor binding and adenylate cyclase activities of glucagon analogues modified in the N-terminal region.
McKee RL; Pelton JT; Trivedi D; Johnson DG; Coy DH; Sueiras-Diaz J; Hruby VJ
Biochemistry; 1986 Apr; 25(7):1650-6. PubMed ID: 3011069
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of glucagon partial agonists and antagonists.
Gysin B; Trivedi D; Johnson DG; Hruby VJ
Biochemistry; 1986 Dec; 25(25):8278-84. PubMed ID: 3814583
[TBL] [Abstract][Full Text] [Related]
11. Structure-function studies on positions 17, 18, and 21 replacement analogues of glucagon: the importance of charged residues and salt bridges in glucagon biological activity.
Sturm NS; Lin Y; Burley SK; Krstenansky JL; Ahn JM; Azizeh BY; Trivedi D; Hruby VJ
J Med Chem; 1998 Jul; 41(15):2693-700. PubMed ID: 9667960
[TBL] [Abstract][Full Text] [Related]
12. Glucagon antagonists. Synthesis and inhibitory properties of Asp3-containing glucagon analogs.
Andreu D; Merrifield RB
Eur J Biochem; 1987 May; 164(3):585-90. PubMed ID: 3032623
[TBL] [Abstract][Full Text] [Related]
13. Pure glucagon antagonists: biological activities and cAMP accumulation using phosphodiesterase inhibitors.
Azizeh BY; Van Tine BA; Trivedi D; Hruby VJ
Peptides; 1997; 18(5):633-41. PubMed ID: 9213355
[TBL] [Abstract][Full Text] [Related]
14. Synthetic peptide antagonists of glucagon.
Unson CG; Andreu D; Gurzenda EM; Merrifield RB
Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4083-7. PubMed ID: 3035568
[TBL] [Abstract][Full Text] [Related]
15. Importance of the C-terminal alpha-helical structure for glucagon's biological activity.
Krstenansky JL; Zechel C; Trivedi D; Hruby VJ
Int J Pept Protein Res; 1988 Dec; 32(6):468-75. PubMed ID: 2854536
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of conformationally constrained glucagon analogues.
Trivedi D; Lin Y; Ahn JM; Siegel M; Mollova NN; Schram KH; Hruby VJ
J Med Chem; 2000 May; 43(9):1714-22. PubMed ID: 10794689
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of seven synthetic glucagon analogs, modified in position 1, 2 and/or 12, on liver and heart adenylate cyclase from rat.
Robberecht P; Waelbroeck M; Camus JC; De Neef P; Coy DH; Christophe J
Peptides; 1986; 7 Suppl 1():109-12. PubMed ID: 3018688
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity studies on the N-terminal region of glucagon.
Sueiras-Diaz J; Lance VA; Murphy WA; Coy DH
J Med Chem; 1984 Mar; 27(3):310-5. PubMed ID: 6699876
[TBL] [Abstract][Full Text] [Related]
19. Characterization of linear and cyclic glucagon analogs by fast atom bombardment mass spectrometry.
Mollova NN; Schram KH; Lin Y; Dharanipragada R; Hruby VJ
Biol Mass Spectrom; 1993 May; 22(5):267-76. PubMed ID: 8507672
[TBL] [Abstract][Full Text] [Related]
20. Glucagon antagonists: contribution to binding and activity of the amino-terminal sequence 1-5, position 12, and the putative alpha-helical segment 19-27.
Unson CG; Gurzenda EM; Iwasa K; Merrifield RB
J Biol Chem; 1989 Jan; 264(2):789-94. PubMed ID: 2536024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
